- WACKER is investing €2 million to build a new reactor for isopropenyl acetate with a capacity of 2,500 metric tons annually.
- The plant's completion is scheduled for the second half of 2017.
- WACKER will take over sales and distribution of calcium acetylacetonate from Acetonate GmbH starting in April.
- Acetonate GmbH will continue producing calcium acetylacetonate, with WACKER handling the annual volume of 900 metric tons.
Investment and Expansion
WACKER BIOSOLUTIONS is enhancing its integrated ketene production at the Burghausen site in Germany by constructing a new reactor for isopropenyl acetate (IPA). This reactor will have an annual capacity of 2,500 metric tons. The project involves a capital expenditure of almost €2 million and is scheduled for completion in the second half of 2017.
Production Process
The new plant will be a significant addition to the Burghausen site's supply chain. In the integrated production system, acetic acid is converted into ketene, then into isopropenyl acetate, and finally into acetylacetone (AcAc). Both IPA and AcAc are essential for various industrial applications, including pharmaceuticals and specialty automotive coatings.
Sales and Distribution
Starting in April, WACKER will take over the sales and distribution of calcium acetylacetonate (Ca-AcAc) from Acetonate GmbH. Although Acetonate GmbH will continue to produce Ca-AcAc, WACKER will manage the entire annual production volume of around 900 metric tons. This strategic move aims to enhance supply chain integration and ensure product quality for customers, particularly in Europe.
